Daiichi Sankyo Gains Marketing Rights To Ajinomoto's Diabetes Drug
Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.
Phase I compound AJD101 has a new mechanism of action that stimulates insulin independent glucose uptake in preclinical studies, according to the two Tokyo-based drug makers.